The Microbiome of Infants Recruited to a Randomised Placebo-controlled Probiotic Trial (PiPS Trial)

Research output: Contribution to journalArticlepeer-review


  • Michael Millar
  • Jo Seale
  • Melanie Greenland
  • Edmund Juszczak
  • Mark Wilks
  • Nicola Panton
  • Kate Costeloe
  • William G Wade

Colleges, School and Institutes

External organisations

  • Barts Health NHS Trust
  • University of Oxford
  • Queen Mary, University of London


The microbial dysbiosis associated with necrotizing enterocolitis (NEC) in preterm infants suggests that early exposure to probiotics may decrease and antibiotics may increase NEC risk. However, administration of Bifidobacterium breve strain BBG-001 to preterm infants did not affect NEC incidence in a multicenter randomised controlled phase 3 trial (PiPS trial). Using a subset of these subjects we compared the fecal microbiome of probiotic and placebo groups and assessed the impact of early antibiotic treatment. Extracted DNA from 103 fecal samples collected at 36weeks post-menstrual age underwent PCR amplification of a fragment of the 16S rRNA gene. Heatmaps were constructed showing the proportions of sequences from bacterial families present at >1% of the community. Stepwise logistic regression assessed the association between early antibiotic exposure and microbiome group. There was no difference in the microbial richness and diversity of the microbiome of preterm infants following treatment with probiotic or a placebo. Conversely, early antimicrobial exposure was associated with different patterns of colonisation, specifically a relative abundance of Proteobacteria. These findings highlight that the potential influence of probiotics on the microbiome of preterm infants remains unclear whereas the modulatory effect of antibiotic exposure on microbial colonisation requires further research.


Original languageEnglish
Pages (from-to)255-262
Number of pages8
Early online date17 May 2017
Publication statusPublished - Jun 2017


  • Journal Article